Price movement over the last 24 hours
abrdn Income Credit Strategies Fund vs Nuwellis Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Nuwellis Inc trades at $2.81 (market cap $1.15M). The key difference: abrdn Income Credit Strategies Fund is far larger — about 570.6× Nuwellis Inc's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| ACP | NUWE | |
|---|---|---|
Market Cap | $656.21M | $1.15M |
Sector | Financials | Technology |
52-Week High | $5.98 | $558.26 |
52-Week Low | $5.01 | $3.05 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | -$662.47K |
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
NUWE trades at $3.29, up 4.44% today, but faces a bearish technical outlook with moving averages signaling a downtrend. The company reported a net loss of $17.52 million in 2025, with a negative net income margin of -217.22%, though it beat earnings expectations in two of the last three quarters. Recent news highlights expansion efforts, including new CEO Mike McCormick outlining strategic priorities and a $6 million public offering closed in June 2026 to support growth.
The outlook remains challenging due to persistent losses and high cash burn, but low valuation ratios like a P/E of 0.64 and P/B of 0.45 may attract value investors. Key risks include the need to achieve profitability and competitive pressures in the medical technology sector. Analyst sentiment is mixed with a 50% buy rating, suggesting cautious optimism amid fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →